The CAR T-cell construct was associated with significantly better progression-free survival than standard-of-care multidrug regimens.

Gareth Morgan, MD, PhD describes the takeaways from the Myeloma XI Trial

Longer PFS with carfilzomib, lenalidomide, and dexamethasone, interim analysis shows

Catherine Diefenbach, MD, discusses the results of the VALERIA study

Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets

Sarah Holstein, MD, leads a roundtable discussion on the CARTITUDE-4 results

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal residual disease.

Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned

No PFS benefit from adding the monoclonal antibody to standard therapy

Study paves the way for quadruple therapy in patients not eligible for a stem cell transplant

Greater efficacy and fewer infusion reactions were seen with methotrexate-pegloticase combination than pegloticase alone in the placebo-controlled MIRROR trial.

Benefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant

Adding brentuximab vedotin to lenalidomide and rituximab significantly reduced the risk for death by 37% in the randomized, placebo-controlled ECHELON-3 trial.

Belamaf plus lenalidomide-dexamethasone achieved encouraging responses

MRD-negativity rates improved across subgroups, supporting daratumumab-lenalidomide combination

Physicians may need to rethink maintenance with lenalidomide (Revlimid and generics) for multiple myeloma.

Lower healthcare costs and efficacy put rituximab ahead of traditional treatments, such as corticosteroids, doxycycline, and immunomodulators, for the autoimmune blistering disease, an expert said.

The two experts based their arguments largely on the same two studies, the only randomized trials to tackle the issue to date.

Patients with early ileocecal Crohn's disease who undergo ileocecal surgery remain off drug treatment 5 years later.

In a new study launched to better understand headache as a side effect of medication use, the top five most frequently implicated meds were all treatments for autoimmune disorders.